The Btk Inhibitor Ibrutinib (PCI-32765) Alone and in Combination with Rituximab for CLL or SLL


The Btk Inhibitor Ibrutinib (PCI-32765) Alone and in Combination with Rituximab for CLL or SLL
Slides from presentations at ASH 2012 and transcribed comments from a recent interview with Bruce D Cheson, MD (1/14/13)
Byrd J et al. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: New and updated results of 116 patients in a Phase Ib/II study. Proc ASH 2012;Abstract 189.

Burger J et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Proc ASH 2012;Abstract 187.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.